What an absolute joke of a business franchise with their disastrous launch and pathetic sales of Fyckcompa, Bumzel and Zonegranny. UCB has wiped the floor clean with Eisai's tight ass (well tighter than a Japanese Eisai geisha rep with all the money the shareholders keep and refuse to invest in marketing budgets). And now they have submitted for a pediatric label - good luck with sales on that....oh wowowow, what's your differentiation, once daily to improve compliance at the risk of inducing aggression and suicide aggression? Patients treated with perampanel had a significantly greater reduction in all-cause hospitalizations compared to those treated with lacosamide, (25.3% vs 30.3%; p=0.0010; respectively). A similar result was seen for epilepsy-related hospitalizations (a reduction of 19.6% vs. 22.6%; p=0.0376, perampanel and lacosamide, respectively). Source: https://www.biospace.com/article/releases/lower-hospitalization-rates-in-epilepsy-patients-treated-with-adjunctive-fycompa-perampanel-ciii/ 5% increase vs. Ucb's Vimpat (lacosamide) at the risk of aggression and suicide ideation????? What's the messaging you idiots? We increase reduction of seizures by 5% but we increase risk of aggression and suicide ideation??????? Here are the bad practices by Eisai: Eisai Downplayed Drug's 'Homicidal' Side Effects, FDA Says https://www.law360.com/articles/1093533/eisai-downplayed-drug-s-homicidal-side-effects-fda-says Less than one week after issuing the Warning Letter to MannKind, on October 11, 2018, OPDP issued an Untitled Letter to Eisai Inc., regarding some oral statements made by a company sales representative in his capacity as an Eisai employee. According to the Letter, a report was submitted as part of a complaint to the OPDP Bad Ad Program, alleging that statements were made to healthcare professionals regarding Fycompa® (perampanel) tablets, providing evidence that the prescription “is intended for new uses for which it lacks approval, and for which its labeling does not provide adequate directions for use.” F-You Eisai and your pathetic team. UCB! UCB! UCB! GW! GW! GW! Arvelle! Arvelle! Arvelle!
Funny post. Good luck getting an intelligent response. It's a good bet that 3/4 of the reps probably couldn't even tell you what the half life is.
Is the European Eisai team still fantasizing Fycompa is a wonder drug? How many peanuts have they sold this year?
I love selling this drug and have a great team. I find it rewarding knowing how many lives are being helped.
Always nice to have corporate post on here. You forgot to include the contact details for media inquiries.
Eisai is the joke of the epilepsy franchises in the pharma industry. The EMA people were making fun of UCB's profit sheet, only to discover UCB makes less sales but has a higher EBITDA!!!!! In 2020 Eisai value at $24 bn vs UCB value at $24 bn Eisai $6.5 sales vs. UCB sales of $5.8 bn Eisai EBITDA $1.5 bn vs. UCB EBITDA $1.6 bn There you go you legacy secretary who became VP of sales and marketing. UCB has a HIGHER PROFIT SHEET than Eisai. F-ing joke.
Let’s see how many Eisai professionals can quote the % of seizure freedom and 50% seizure reduction of their epilepsy drugs. Let me start with Fycrapa - 4% seizure freedom in partial onset epilepsy. Hahahahahahahaha.
Yet you continue to post and reply to your own posts over and over. Your departure was celebrated by every dept. at Eisai. HR is still cheering, it was the best possible way to be rid of you.
lol! You think I’m an ex-Eisai employee?! Wow, the situation at Eisai is even worse than I thought! By the way are you “Eisai’s best kept secret”?
"Among the adult epilepsy patients with effectiveness assessed by seizure type, patients with focal seizures only, had seizure freedom and responder rates of 14.5% and 44.6% at the last visit." Eisai Presents Its Largest Real-World Study Of Anti-Epileptic Drug FYCOMPA® (perampanel) Across Patient Types At The 2021 American Epilepsy Society (AES) Annual Meeting Sorry, but Xcopri/Ontozry still kicks your a......with less side effects. Oh wait - Fycompa is once a day. What a great "hook" story. Oh sorry, Xcopri/Ontozry is also once a day. Damn! You thought you had an advantage there! https://www.ema.europa.eu/en/documents/product-information/ontozry-epar-product-information_en.pdf Would I advise a doctor to prescribe Fycompa vs. Ontozry? Let me see the list of side effects of Fycompa? Side Effects - FYCOMPA® (perampanel) CIII Can FYCOMPA affect my mood and behavior? FYCOMPA may cause mental (psychiatric) problems, including: new or worse aggressive behavior (including homicidal behavior), hostility, anger, anxiety, or irritability; being suspicious or distrustful (believing things that are not true); seeing objects or hearing things that are not there; confusion; difficulty with memory; other unusual or extreme changes in behavior or mood. Tell your healthcare provider right away if you have any new or worsening mental problems while taking FYCOMPA. Now let me see the list of side effects of Xcopri/Ontozry Ontozry | European Medicines Agency The most common side effects with Ontozry (which may affect more than 1 in 10 people) are sleepiness, headache and problems with keeping balance. Ontozry should not be used by patients with familial short QT syndrome, a rare genetic condition that can lead to irregular heart rhythm. For the full list of restrictions and side effects, see the package leaflet. FYCOMPA - ARE YOU JOKING????????????
He/she/trans etc is not feeling threatened. Just good old counter messaging to further demotivate Eisai sales reps and MSLs. Eisai ASDs suck balls.
